TR115 versus standard care for resistant T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called TR115 versus your doctor's choice of standard treatment for peripheral T-cell lymphoma that has come back or stopped responding to prior treatments. TR115 may help control this rare blood cancer by targeting specific cancer pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peripheral T-cell lymphoma (a rare type affecting immune cells) and it has returned or stopped responding to previous treatments
- You have received at least one prior therapy and tried at least one newer drug like chidamide, pralatrexate, or brentuximab vedotin—or were unable to tolerate these
- You are at least 18 years old and in good enough health to tolerate treatment (ECOG 0–1: able to do normal activities or mostly able)
- Your lymphoma can be seen on imaging scans (at least one enlarged lymph node or tumor ≥1.0 cm)
- Your blood counts, liver, kidney, and heart function are adequate for treatment; your heart's pumping ability is normal
- You are willing to provide a tumor sample (archived or newly collected) and expect to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for patients with T-cell or NK/T-cell lymphomas that have stopped responding to previous treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.